BCT BriaCell Therapeutics Corp

Note from BriaCell Management – October is Breast Cancer Awareness Month

Note from BriaCell Management – October is Breast Cancer Awareness Month
EN
01/10/2020

Underlying

BCTBriaCell Therapeutics Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BriaCell Therapeutics Corp

 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Announces Positive Recommendation from Data Safety Monitoring...

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by DSMBStudy is being conducted under FDA Fast Track Designation PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a...

June 24, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Announces Virtual Investor Presentations on Thursday, June 12...

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briace...

June 4, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ...

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients in the literatureMeaningful Clinical Benefit observed in all MBC subtypes, including HER2+, HR+/HER2-, and triple-negative breast cancer (TNBC)Overall survival and clinical benefit data reported ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses Fir...

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage settingPhase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer First Bria-OTS monotherapy patient remains on study with confirmed resolution of lung metastasis PHILADELPHIA and VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinica...

May 27, 2025 1 EN
 PRESS RELEASE
Free
BCT BriaCell Therap...

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Dat...

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations Successful completion of the pivotal Phase 3 study may support Biologics License Application, Priority Review, Full Approval, and Commercialization PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch